Medical/Pharmaceuticals

Classys Emerges as a Global Leader in Medical Aesthetics Beyond K-Beauty, Highlighting 45% Growth, 50%+ Margins, and Recurring Revenue Model

– Operations in 80+ countries with over 45,000 installed platforms and 66% international revenue mix – Consumables account for 46% of revenue, with more than 5.5 million HIFU procedures performed annually worldwide – Accelerating growth through two strategic M&A transactions over the past two yea...

2026-04-27 21:00 4022

WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026

* Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY * Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion * Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI ,April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 60...

2026-04-27 17:03 4239

IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical

TOKYO, April 27, 2026 /PRNewswire/ -- IMG Pharmaceutical Co., Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a Japanese pharmaceutical manufacturer...

2026-04-27 16:35 3378

Eyebright Medical Releases Its 2025 Annual Report and Sustainability Report

Innovation Drives Strong Results, While Global Expansion and ESG Practices Progress Steadily HONG KONG, April 27, 2026 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", "the Company", Stock Code: 688050.SH, together with its subsidiaries collectively referred...

2026-04-27 09:00 3483

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRN...

2026-04-27 08:10 4490

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...

2026-04-26 19:00 4390

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study

* High Impact Session presented at Heart Rhythm Society's Congress in Chicago * First time showing results of new Less Invasive approach * Improvement in Left Ventricular Ejection Fraction (LVEF), 6 Minute Walk Test (6MWT), Quality of Life (QOL) and New York Heart Association (NYHA) class. C...

2026-04-25 04:00 3627

MALAYSIA HEALTHCARE RETURNS TO MEDAN AS INDONESIAN PATIENTS SEEK TRUSTED SECOND OPINIONS ABROAD

MEDAN, Indonesia, April 25, 2026 /PRNewswire/ -- Malaysia has steadily emerged as one of the most trusted destinations for Indonesian patients seeking timely and reliable care. Following its last major outreach in 2022, Malaysia Healthcare returns to Medan this year, reconnecting with a community...

2026-04-25 02:10 4441

The World's First Open-Source Medical Video LLM Released, Calling the Global Developer Community to Push It Further

SHANGHAI, April 24, 2026 /PRNewswire/ -- United Imaging Intelligence (UII) has unveiled uAI NEXUS MedVLM, a pioneering Medical Video Large Language Model that delivers unprecedented spatial and temporal precision in clinical environments. UII is fully open-sourcing the model and introducing a new...

2026-04-24 21:19 3727

Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...

2026-04-24 21:00 2638

Quasar Medical Celebrates Grand Opening of New Manufacturing Facility in Thailand

The new Chonburi facility increases global manufacturing capacity and strengthens regional supply chain capabilities for leading MedTech customers CHONBURI, Thailand, April 24, 2026 /PRNewswire/ -- Quasar Medical, a global leader in the manufacturing of interventional and minimally invasive medic...

2026-04-24 20:30 2443

Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy

* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...

2026-04-24 20:00 3211

CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

* Patient-specific titanium implant designed for cranial and craniofacial reconstruction * First Korean company to obtain FDA 510(k) clearance for a customized titanium implant in the U.S. market SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- CGBIO (CEO: Hyunseung Yu) announced that its...

2026-04-24 20:00 2453

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...

2026-04-24 19:30 2597

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...

2026-04-24 19:03 2734

CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair

Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...

2026-04-24 14:58 2760

Award-Winning XERF™ The Structural Skin Tightening Device, Now Available in Singapore

Cynosure Lutronic's non-invasive facial lifting and tightening device XERF™, recognised at the SBR Technology Excellence Awards 2026 is now offered at aesthetic clinics across Singapore. SINGAPORE, April 23, 2026 /PRNewswire/ -- Patients in Singapore now have access to XERF™, Cynosure Lutronic's...

2026-04-24 13:08 2673

Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments

* 74 healthcare professionals from 13 countries attended, recognizing the value of PrabotulinumtoxinA's "Safety" * Comprehensive program including anatomy sessions, proprietary injection techniques, and 1:1 hands-on training * Global participants praise the program as "a platform to share pr...

2026-04-24 11:16 3798

EVERISE NAMED LEADER IN EVEREST GROUP'S HEALTHCARE CUSTOMER EXPERIENCE MANAGEMENT PEAK MATRIX® 2026

PLANTATION, Fla., April 23, 2026 /PRNewswire/ -- Leading global healthcare customer experience provider Everise today announced that it has been named a Leader in Everest Group's Healthcare Customer Experience Management (CXM) Intelligent Operations PEAK Matrix® Assessment 2026 for the first time...

2026-04-23 21:00 2446

Servier completes the acquisition of Day One Biopharmaceuticals

* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma.  * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs.  * Transaction represents total equity ...

2026-04-23 20:30 3574
1 ... 6789101112 ... 649